Press Releases Archives - Page 8 of 103 - Lupin

BSE 2300.00 NSE 2307.90

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2300.00 NSE 2307.90

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States

Lupin Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025

February 27, 2025

Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

February 21, 2025

Lupin Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security

February 19, 2025

Lupin Q3 FY2025 Results

February 12, 2025

Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%

February 10, 2025

Lupin and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

February 10, 2025

Lupin Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets

February 3, 2025

Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations

February 1, 2025

Lupin Receives Approval from U.S. FDA for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.06%

January 28, 2025

1 2 … 7 8 9 … 102 103

Search

Hit enter to search or ESC to close